Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 265-111-0 | CAS number: 64742-11-6 A complex combination of hydrocarbons obtained as the extract from a solvent extraction process. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly in the range of C20 through C50. This stream is likely to contain 5 wt. % or more of 4- to 6-membered condensed ring aromatic hydrocarbons.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliability 2. Research study, small group sizes (3 female), no guideline and not GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
- Objective of study:
- absorption
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Examined bioavailability in pregnant rats following dermal application 1000 mg/kg of radiolabelled test material on gestation days 10, 11, and 12. Maternal tissues, blood, placentas, uteri, embryos, and yolk sacs were collected and analyzed for radioactivity on gestation day 13 following sacrifice. Urine, faeces, and cage wash was collected every 24 hours and also analyzed for radioactivity.
- GLP compliance:
- not specified
Test material
- Reference substance name:
- 64742-04-7
- Cas Number:
- 64742-04-7
- IUPAC Name:
- 64742-04-7
- Reference substance name:
- 318 isthmus furfural extract
- IUPAC Name:
- 318 isthmus furfural extract
- Test material form:
- liquid: viscous
- Details on test material:
- - Name of test material (as cited in study report): 318 isthmus furfural extract
- Substance type: Vacuum distillate treated with furfural solvent; treated distillate aromatic extract; CRU # 86187
- Physical state: Liquid
- Expiration date of the lot/batch: 1991-04-30
- Density: 0.98 g/mL
Constituent 1
Constituent 2
- Radiolabelling:
- yes
- Remarks:
- 14C-carbazole and 3H-benzo(a)pyrene
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories
- Age at study initiation: 9 weeks old
- Weight at study initiation: Not reported
- Fasting period before study: Not reported
- Housing: Housed in individual metabolism cages
- Individual metabolism cages: Yes
- Diet (e.g. ad libitum): Ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: from 1988-08-30 to 1988-09-12
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 22 °C
- Humidity (%): 40 to 60%
- Air changes (per hr): Not reported
- Photoperiod (hrs dark / hrs light): 12 hours light/ 12 hours dark
IN-LIFE DATES: Not reported
Administration / exposure
- Route of administration:
- dermal
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: Not reported
- % coverage: Not reported
- Type of wrap if used: protective device; Not reported
- Time intervals for shavings or clippings: Not reported
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Not reported
- Time after start of exposure: Not reported
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 1000 mg/kg bw
- concentration (if solution): Undiluted
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not reported
- Amount(s) applied (volume or weight with unit): Not reported
- Concentration (if solution): Not reported
- Lot/batch no. (if required): Not reported
- Purity: Not reported
USE OF RESTRAINERS FOR PREVENTING INGESTION: Yes; Elizabethan-style collar - Duration and frequency of treatment / exposure:
- Test material was applied dermally on gestation days 10, 11, and 12.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw
- No. of animals per sex per dose / concentration:
- Three females
- Control animals:
- other: yes, but not for bioavailability group (9)
- Positive control reference chemical:
- Not reported
- Details on study design:
- - Dose selection rationale: Not reported
- Rationale for animal assignment (if not random): N/A - Details on dosing and sampling:
- PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled (delete / add / specify): Blood, thymus, liver, small intestine, large intestine, kidneys, stomach, and ovaries. Placenta, embryos, amniotic fluid, and yolk sacs were pooled for each dam. Urine and faeces were also collected.
- Time and frequency of sampling: Tissues were collected upon sacrifice on gestation day 13. Urine and faeces were collected every 24 hours until sacrifice.
- Other: Body weight was measured on gestation days 0, 3, 6, and 10.
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled (delete / add / specify): N/A
- Time and frequency of sampling: N/A
- From how many animals: N/A
- Method type(s) for identification (e.g. GC-FID, GC-MS, HPLC-DAD, HPLC-MS-MS, HPLC-UV, Liquid scintillation counting, NMR, TLC): N/A
- Limits of detection and quantification: N/A
Results and discussion
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- Dermal absorption of 14C-carbazole occurred more extensively than did 3H-benzo9a)pyrene over a 72 hour period. About 19.9% of the total applied 14C-radioactive dose was dermally absorbed. About 4.1% of the total applied 3H-benzo(a)pyrene dose was systemically absorbed.
- Details on distribution in tissues:
- Of the total absorbed dose of 14-C-carbazole 2.1% was found in the maternal tissues and less than 0.01% was detected in the embryo. 0.75% of the radioactive dose was found in the maternal blood, 0.58% in the large intestine, 0.10% in small intestine, 0.21% in liver. The amount of 3H-BaP found in maternal tissues and embryo at the end of 72 hours was 1.8% and less than 0.01%, respectively, of the total administered dose. 0.54% of the radioactive dose was found in the large intestine, 0.08% in the small intestine, 0.12% in the liver, and 0.13% in the maternal blood.
- Details on excretion:
- 17.7% of 14C-carbazole was excreted in the urine and faeces over 72 hours. 2.3% of 3Hbenzo(a)pyrene was excreted in the urine and faeces over 72 hours.
Metabolite characterisation studies
- Metabolites identified:
- no
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): low bioaccumulation potential based on study results
Less than 0.01% of the 14C-carbazole or 3H-benzo(a)pyrene in the radioactive dose of 318 isthmus furfural extract was detected in the embryos. Neither 14C-carbazole nor 3H-benzo(a)pyrene were found to selectively accumulate in the embryo. These findings indicate that the placenta serves as an effective barrier against the transport of carbozole and benzo(a)pyrene to the embryo. - Executive summary:
- In a bioavailability toxicokinetics study in
pregnant rats, radiolabelled 318 isthmus furfural extract was applied dermally,
a t a dose of 1000 mg/kg, on gestation days 10, 11, and 12. Maternal
tissues, blood, placentas, uteri, embryos, and yolk sacs were collected
and analyzed for radioactivity on gestation day 13 following sacrifice.
Urine, faeces, and cage wash was collected every 24 hours and also
analyzed for radioactivity.
Dermal absorption of 14C-carbazole occurred more extensively than did 3H-benzo9a)pyrene over a 72 hour period. About 19.9% and 4.1% of the total applied of 14C-carbazole and 3H-benzo(a)pyrene, respectively, was dermally absorbed. Of the total absorbed dose of 14-C-carbazole, 2.1% was found in the maternal tissues and less than 0.01% was detected in the embryo. Of the total absorbed dose of 3H-benzo(a)pyrene 1.8% was detected in the maternal tissue and less than 0.01% was found in the embryo. 17.7% of 14C-carbazole was excreted in the urine and faeces over 72 hours. 2.3% of 3Hbenzo(a)pyrene was excreted in the urine and feces over 72 hours.
Based on the bioavailability results, neither of the radiolabelled components of 318 isthmus furfural extract were found to selectively accumulate in the embryo.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.